OptimizeRx Cuts Sales Outlook To $87 Million–$93 Million While Quarterly Profit Rises
A major customer's spending has resumed, but cost cuts are doing more of the work in protecting profitability.
OptimizeRx, which helps pharmaceutical companies advertise to healthcare providers and patients, cut its 2026 sales outlook to $87 million–$93 million Wednesday while keeping its adjusted EBITDA forecast intact. The announcement, included in Friday's SEC filing, paired weaker customer spending with higher third-quarter profit.
A Returning Customer Isn't Enough
Third-quarter revenue fell 17% to $21.6 million from $26.1 million a year earlier. On Wednesday's earnings call, management attributed the decline mainly to spending cuts by a small group of large customers, including buyers of lower-margin managed advertising services, and delayed spending decisions.
One customer that supplied 10% of revenue in 2025 spent nothing during the first nine months of 2026. The customer has resumed spending in the fourth quarter, but below its historical level.
Chief Executive Officer Stephen L. Silvestro said contracted revenue for 2026 is approximately 20% below the comparable year-earlier level. The outlook cut reflects limited visibility into additional customer purchases: “We just haven't seen the buy-up growth yet that we are anticipating,” he said on the earnings call.
Chief Business Officer Andy D'Silva said contracted revenue covers a little over 90% of what the company needs to reach the full-year outlook's midpoint, compared with roughly 95% in recent years. Securing additional campaigns also means delivering and measuring them before revenue can be recognized.
OptimizeRx sells audience targeting, campaign planning and ad delivery through electronic health records, prescribing software and consumer media. Customer concentration makes individual spending decisions consequential: its five largest customers supplied approximately 47% of 2025 revenue.
Lower Costs Protect The Bottom Line
Net income rose to $1.2 million, or $0.06 per basic and diluted share, from $0.8 million, or $0.04 per share, a year earlier. Adjusted net income reached $3.8 million, or $0.20 per diluted share, versus $3.1 million, or $0.16.
Adjusted EBITDA—a measure excluding interest, taxes, depreciation and certain other costs—rose to $6.3 million from $5.1 million. Its margin reached approximately 29%, versus approximately 20% a year earlier.
Silvestro credited “improved product mix and cost management initiatives” in the earnings release. Management said first-half cost reductions helped the company operate more efficiently, while reduced lower-margin consumer advertising work improved the sales mix.
Quarterly expenses fell to $18.9 million from $24.0 million, even with $0.7 million in severance costs. OptimizeRx retained its full-year adjusted EBITDA outlook of $21 million to $25 million.
Debt Falls, Buybacks Come Next
Operating cash flow totaled $12.9 million for the first nine months of 2026, compared with $11.6 million a year earlier. Cash stood at $22.3 million at September 30, versus $23.4 million at December 31, 2025.
OptimizeRx has repaid $9.3 million of loan principal since June 30. That includes $6.3 million during the third quarter and another $3 million after quarter-end, leaving $10.4 million outstanding.
Chief Financial and Strategy Officer Edward Stelmakh said management expects more share repurchases in the fourth quarter while continuing to repay debt ahead of schedule.
For sales recovery, management is looking to the returning customer and newer distribution relationships with advertising platforms DeepIntent, The Trade Desk and PulsePoint. Silvestro said contracted revenue for 2027 was about 20% ahead of the comparable year-earlier point, while cautioning that the campaign-planning season is still early.
The immediate task is to turn additional fourth-quarter customer spending into completed campaigns and recognized revenue; management has kept its earnings-measure forecast intact while lowering the sales bar.
Sources
- 8-K Filing — OptimizeRx Corp (OPRX) — SEC EDGAR
- Exhibit oprxq32026earningsrelease.htm — OptimizeRx Corp 8-K exhibit — SEC EDGAR
- Exhibit ex992transcript.htm — OptimizeRx Corp 8-K exhibit — SEC EDGAR
- OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance – Company Announcement - FT.com — Financial Times
- OptimizeRx Reports Third Quarter 2026 Financial Results and — globenewswire.com